
MGTX Stock Forecast & Price Target
MGTX Analyst Ratings
Bulls say
MeiraGTx Holdings is viewed positively because it combines a differentiated clinical pipeline with meaningful non-dilutive financing, reducing near-term funding risk while preserving upside from its lead assets. The company now expects bota-vec’s FDA BLA filing in 2026 and a first commercial launch in 2027, while xerostomia is fully enrolled in Phase II with a 2Q27 readout, mid-’27 BLA filing, and early-’28 U.S. launch potential. Financially, it reported $321 million of revenue in 2Q26, ended with $145 million in cash, and said its runway extends into 2H28, supported by strategic capital from Oberland and Hologen plus in-house GMP manufacturing and proprietary vector platforms.
Bears say
MeiraGTx Holdings is a clinical-stage genetic medicines company whose valuation depends heavily on pipeline success, making it vulnerable to clinical program execution risk, regulatory uncertainty, and the possibility that key programs fail to demonstrate efficacy. Its focus on high-unmet-need diseases such as radiation-induced xerostomia, Parkinson’s disease, and AIPL1-associated retinal dystrophy does not eliminate the risk that safety signals, competition, or intellectual property disputes could delay or impair commercialization. Although its vertical integration and in-house manufacturing capabilities provide operational control, the company still faces long-term pricing pressure and remains exposed to the inherent uncertainty of advancing multiple unproven therapies from development to market.
This aggregate rating is based on analysts' research of MeiraGTx Holdings plc and is not a guaranteed prediction by Public.com or investment advice.
MGTX Analyst Forecast & Price Prediction
Start investing in MGTX
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About MeiraGTx Holdings plc (MGTX) Forecast
MGTX Analyst Forecast & Price Prediction
Start investing in MGTX
Order type
Buy in
Order amount
Est. shares
0 shares